查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928655

PSMA靶向放射性藥物偶聯物市場（按放射性核種類型、適應症、治療類型、患者年齡層、最終用戶和分銷管道分類），全球預測，2026-2032年

Targeted PSMA Radionuclide Drug Conjugates Market by Radionuclide Type, Indication, Therapy Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，標靶 PSMA 放射性核種藥物偶聯物市場價值為 9.3575 億美元，預計到 2026 年將成長至 10.3407 億美元，到 2032 年將達到 20.2025 億美元，複合年成長率為 11.62%。

關鍵市場統計數據
基準年 2025 9.3575億美元
預計年份：2026年 1,034,070,000 美元
預測年份 2032 2,020,250,000 美元
複合年成長率 (%) 11.62%

將PSMA靶向放射性核素偶聯物（PSMA-RNCs）的興起定位為臨床和商業性的轉折點，需要綜合運用科學和市場觀點。

前列腺特異性膜抗原 (PSMA) 靶向放射性核素藥物偶聯物代表了分子標靶技術和放射性藥物科學的融合，正在重塑前列腺腫瘤的治療和診斷方法。近期臨床進展已證實 PSMA 是放射性核種遞送的高價值靶點，可實現惡性組織的成像和治療性切除，從而實現更精準的患者篩選和個體化治療。因此，藥物研發人員、影像專家、臨床試驗團隊和支付方正在重新審視其產品組合和臨床路徑，以將治療性診斷策略整合到標準治療方案中。

科學突破、監管調整和生產創新將如何共同重塑PSMA放射性核素療法的臨床開發和醫療服務？

在科學進步、監管變革和治療路徑重組的推動下，PSMA標靶放射性核治療領域正經歷著變革性的轉變。 α發射同位素因其高線性能量傳遞率和克服抗藥性機制的潛力而備受關注，而BETA發射同位素則因其安全性和有效性已得到充分驗證，從而支持其更廣泛的臨床應用。同時，影像學和治療診斷技術的進步正在改善患者篩選和療效監測，這些技術的結合推動臨床試驗設計轉向適應性強、生物標記增強型方法。

評估美國累積關稅變化對營運和策略的影響，以及對放射性藥物供應鏈韌性的影響。

預計美國2025年的政策變化和關稅調整為放射性藥物供應鏈帶來了新的商業性複雜性。進口組件、專用放射化學設備和前驅材料的關稅可能會增加採購成本，擠壓製造商的利潤空間。這給採購決策、合約結構和價格談判帶來了壓力。為此，許多相關人員正在重新評估其供應商組合，並尋求更多本地夥伴關係關係，以對沖關稅相關的波動風險，並確保對時效性同位素的持續供應。

分析臨床、治療、分銷和人口統計細分市場，以確定PSMA放射性核種產品的客製化開發和商業化路徑

對PSMA放射性核種領域進行細分，對於優先進行臨床開發和商業化至關重要。依放射性核種類型進行分析涵蓋α和BETA發射體以及診斷同位素。具體而言，錒-225因其α發射體療效而備受關注，鎵-68用於PET成像和診斷，鎦-177作為具有成熟臨床記錄的治療性BETA發射體，锝-99m則適用於更易於應用的成像Technetium。每種放射性核素都具有獨特的放射生物學特性、生產和物流要求以及監管方面的考量，這些都會影響候選藥物的選擇和臨床定位。

臨床開發、生產能力和報銷策略的區域比較（美洲、歐洲、中東和非洲、亞太地區）

區域趨勢正在塑造PSMA靶向放射性核素偶聯物的臨床開發生態系統和商業性准入策略，美洲、歐洲、中東和非洲以及亞太地區呈現出不同的營運和監管現狀。在美洲，成熟的臨床試驗基礎設施、完善的核子醫學網路以及不斷完善的放射性藥物監管體系，營造了有利於快速臨床轉化和早期商業性化的環境，同時也加劇了對放射化學能力和專業人才的競爭。

分析公司策略，這些策略結合了平台差異化、生產控制和臨床整合，以增強其在放射性藥物領域的競爭優勢。

PSMA放射性核種領域主要企業的發展趨勢圍繞著策略聯盟、放射化學能力的垂直整合以及臨床開發生態系統的建構。領先的開發商強調平台的多功能性，將候選藥物與多種放射性核素結合，以最佳化治療指數並支持治療診斷（治療診斷學）應用。將放射性藥物開發商與迴旋加速器營運商、專科藥房和學術臨床中心聯繫起來的合作模式正變得越來越普遍，以解決生產限制以及設施對複雜處理和給藥的準備。

為高階主管實現PSMA放射性核種療法的供應彈性、監管合規性和臨床應用，制定切實可行的策略支柱

產業領導者必須採取多管齊下的策略，將PSMA靶向放射性核種偶聯物的科學潛力轉化為持續的臨床和商業性成功。首先，要減少對單一來源的依賴，並透過投資可與關鍵測試設施毗鄰的靈活生產模式，來克服短壽命同位素固有的物流障礙。同時，也應建立關鍵前驅和設備的長期供應協議和冗餘備份，從而降低貿易和地緣政治動盪帶來的風險。

報告採用透明的調查方法，說明了專家訪談、技術文獻綜述和營運分析，這些都構成了報告結論和建議的基礎。

本研究綜合分析採用多方法論，結合了專家訪談、同行評審的臨床研究和監管指南的文獻綜述，以及放射性藥物和物流實踐的營運分析。專家諮詢對象包括核子醫學和腫瘤內科的臨床醫生、具有放射性藥物經驗的監管事務專業人員、放射化學公司的生產和供應鏈經理，以及參與進行複雜臨床試驗的臨床營運專業人員。這些訪談提供了關於臨床決策、設施準備以及同位素處理操作限制的定性見解。

透過協作的方式整合臨床、營運和商業性需求，從而實現PSMA放射性核素療法的成功以及更廣泛的臨床整合。

累積分析表明，PSMA靶向放射性核素藥物偶聯物代表了前列腺癌治療的模式轉移，實現了精準干預，充分利用了影像和治療的互補優勢。放射性核種選擇技術的進步，加上影像技術的改進和整合的臨床路徑，拓展了治療的可能性，同時也帶來了必須積極應對的生產、監管和報銷方面的挑戰。該領域的成功同樣依賴臨床療效、營運可行性、供應鏈韌性以及整個醫療生態系統中相關人員之間的協作。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依放射性核種類型分類的PSMA標靶放射性藥物偶聯物市場

  • 錒-225
  • 鎵-68
  • 鎦-177
  • Technetium-99m

9. 依適應症分類的PSMA標靶放射性偶聯物市場

  • 轉移性去勢去勢抗性前列腺癌
  • 轉移性去勢敏感性前列腺癌
  • 非轉移性前列腺癌

第10章 PSMA靶向放射性藥物偶聯物市場（按治療方法分類）

  • 聯合治療
  • 單藥治療

11. 依患者年齡層分類的PSMA標靶放射性偶聯藥物市場

  • 成年人（18-65歲）
  • 老年人（65歲以上）

第12章 PSMA靶向放射性藥物偶聯物市場（按最終用戶分類）

  • 診所
  • 醫院
  • 診斷影像中心
  • 研究所

13. PSMA靶向放射性偶聯物市場（按分銷管道分類）

  • 直接購買
  • 醫院藥房
  • 專科藥房

14. 按地區分類的PSMA標靶放射性偶聯物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 PSMA靶向放射性偶聯物市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國PSMA標靶放射性偶聯物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國PSMA標靶放射性偶聯物市場

18. 中國PSMA標靶放射性藥物偶聯物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • ACUITY Pharmaceuticals, Inc.
  • Advanced Accelerator Applications
  • Bayer AG
  • Curium Pharma SA
  • Endocyte Therapeutics GmbH
  • GE Healthcare Limited
  • Isoray Medical, Inc.
  • ITM Isotope Technologies Munich SE
  • Jubilant Life Sciences Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Point Biopharma Global Inc.
  • Point Biopharma Inc.
  • PSMA Therapeutics LLC
  • RadioMedix, Inc.
  • Sorrento Therapeutics, Inc.
  • Telix Pharmaceuticals Limited
  • Telix Pharmaceuticals Pty Ltd
  • Theragnostics, Inc.
  • Viamet Pharmaceuticals, Inc.
Product Code: MRR-92740D85F094

The Targeted PSMA Radionuclide Drug Conjugates Market was valued at USD 935.75 million in 2025 and is projected to grow to USD 1,034.07 million in 2026, with a CAGR of 11.62%, reaching USD 2,020.25 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 935.75 million
Estimated Year [2026] USD 1,034.07 million
Forecast Year [2032] USD 2,020.25 million
CAGR (%) 11.62%

Framing the rise of PSMA-targeted radionuclide conjugates as a clinical and commercial inflection point that demands integrated scientific and market perspectives

Prostate-specific membrane antigen (PSMA) targeted radionuclide drug conjugates represent a convergence of molecular targeting and radiopharmaceutical science that is reshaping therapeutic and diagnostic approaches in prostate oncology. Recent clinical progress has validated PSMA as a high-value target for delivering radionuclides that can both image and therapeutically ablate malignant tissue, thereby enabling more precise patient selection and treatment personalization. As a result, drug developers, imaging specialists, clinical trial teams, and healthcare payers are reassessing portfolios and clinical pathways to integrate theranostic strategies into standard of care.

This report synthesizes cross-disciplinary evidence and stakeholder perspectives to present a cohesive understanding of the technical, clinical, and commercial dynamics influencing PSMA-targeted radionuclide drug conjugates. It examines radionuclide selection criteria, clinical indication differentiation, therapeutic modalities, delivery and administration imperatives, and end-user workflows. By grounding the discussion in operational realities-such as manufacturing complexity, regulatory pathways, and logistics-it aims to equip decision-makers with the context necessary to prioritize investments, design robust clinical programs, and align market access strategies with evolving standards of care.

Through an evidence-focused lens, the introduction sets the stage for deeper analysis by highlighting how advances in alpha and beta emitters, improvements in imaging diagnostics, and evolving care models are collectively expanding the therapeutic potential of PSMA-targeted conjugates while creating new operational and commercial challenges that stakeholders must address.

How scientific breakthroughs, regulatory adaptation, and manufacturing innovation are collectively reconfiguring clinical development and care delivery for PSMA radionuclide therapeutics

The landscape of PSMA-targeted radionuclide therapeutics is undergoing transformative shifts driven by scientific advances, regulatory evolution, and care pathway reconfiguration. Alpha-emitting isotopes have gained prominence for their high linear energy transfer and potential to overcome resistance mechanisms, while beta emitters continue to provide well-characterized safety and efficacy profiles that support broader clinical adoption. Concurrently, improved imaging agents and theranostic pairing enhance patient selection and response monitoring, which together shift clinical trial design toward adaptive and biomarker-enriched approaches.

Moreover, regulatory frameworks are adapting to the unique nature of radiopharmaceuticals, with agencies showing greater willingness to consider composite endpoints and imaging-based selection criteria that can accelerate evidence generation. Payer landscapes are likewise evolving, albeit more conservatively, as real-world evidence and health economic modeling begin to demonstrate value beyond traditional survival endpoints. In parallel, manufacturing paradigms are transitioning to accommodate demand for short-lived isotopes through regionalized production hubs, modular radiochemistry platforms, and closer integration with clinical sites to minimize decay loss and logistical inefficiency.

These converging shifts are prompting sponsors to re-evaluate trial geography, partner ecosystems, and commercialization tactics. Strategic alliances between academic centers, radiochemistry innovators, and specialty pharmacies are becoming a practical necessity rather than an optional enhancement. As a result, the industry is moving from isolated proof-of-concept activities to coordinated, scalable programs that balance clinical rigor with operational feasibility, which ultimately catalyzes broader access and integration of PSMA radionuclide therapeutics into multidisciplinary oncology care.

Evaluating the operational and strategic repercussions of cumulative tariff shifts in the United States and their implications for radiopharmaceutical supply chain resilience

Anticipated policy changes and tariff adjustments in the United States in 2025 have introduced a new dimension of commercial complexity for radiopharmaceutical supply chains. Tariff measures on imported components, specialized radiochemistry equipment, or precursor materials can elevate procurement costs and compress manufacturer margins, which in turn pressures decisions around sourcing, contract structures, and pricing negotiations. In response, many stakeholders are reassessing supplier portfolios and exploring nearer-shore partnerships to hedge against tariff-related volatility and to secure continuity for time-sensitive isotopes.

Beyond direct cost implications, cumulative tariff effects propagate through logistical networks that are already constrained by the decay characteristics of radionuclides and the need for tightly controlled cold chain and regulatory-compliant transport. This layering of trade policy over operational constraints emphasizes the strategic value of distributed manufacturing models and local radiopharmacy capacity that reduce cross-border movement of critical materials. Consequently, sponsors and service providers are realigning capital expenditure plans and prioritizing investments that increase domestic resilience, whether that means co-locating radiochemistry nodes with clinical trial sites or establishing long-term supply agreements with regional cyclotron operators.

At the same time, tariff-driven pressures are incentivizing more creative contracting between developers and payers, including value-based arrangements and outcomes-linked reimbursement that can mitigate short-term cost increases. Importantly, these dynamics are also accelerating collaborative advocacy efforts to clarify regulatory expectations and to secure exemptions or mitigations for clinically essential materials. Taken together, the cumulative effect of tariff changes is catalyzing structural adaptation across the ecosystem, prompting a rebalancing of cost, access, and operational risk in the delivery of PSMA-targeted radionuclide therapies.

Dissecting clinical, therapeutic, distributional, and demographic segments to reveal tailored development and commercial pathways for PSMA radionuclide products

A granular understanding of segmentation is critical for prioritizing clinical development and commercialization pathways in the PSMA radionuclide space. Analysis by radionuclide type spans alpha and beta emitters and diagnostic isotopes, specifically Actinium-225 for alpha-emitter potency, Gallium-68 for PET imaging and diagnostics, Lutetium-177 for therapeutic beta emissions with established clinical precedent, and Technetium-99m for accessible imaging applications. Each radionuclide brings distinct radiobiological profiles, production and logistics requirements, and regulatory considerations that influence candidate selection and clinical positioning.

Indication-specific segmentation covers metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, and non-metastatic prostate cancer. These indications differ in clinical endpoint expectations, treatment sequencing, and patient heterogeneity, which affects trial design and evidence generation strategies. Therapeutic modality-whether pursued as combination therapy with established systemic agents or as monotherapy-dictates safety evaluation priorities and combination toxicity management, while also shaping value propositions for clinicians and payers.

End-user segmentation identifies clinical settings such as clinics, hospitals, imaging centers, and research institutes where administration and operational workflows vary significantly. Distribution channel considerations, including direct purchase, hospital pharmacy provisioning, and specialty pharmacy networks, determine procurement pathways and influence reimbursement negotiation. Administration route segmentation, centered on intravenous injection, underscores the procedural requirements and staff competencies necessary for safe delivery. Patient age group segmentation differentiates adult populations aged 18 to 65 from senior cohorts aged 65 and above, reflecting divergent comorbidity profiles and tolerance considerations that must be integrated into clinical development and marketing strategies.

Comparative regional considerations for clinical development, manufacturing capacity, and reimbursement strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape both clinical development ecosystems and commercial access strategies for PSMA-targeted radionuclide conjugates, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct operational and regulatory realities. In the Americas, mature clinical trial infrastructure, established nuclear medicine networks, and progressive regulatory engagement for radiopharmaceuticals create an environment conducive to rapid clinical translation and early commercial entry, while also intensifying competition for radiochemistry capacity and trained personnel.

The Europe, Middle East & Africa region offers heterogeneous regulatory pathways and reimbursement systems that require nuanced market entry approaches. In many European countries, strong academic collaborations and centralized radiopharmacy capabilities facilitate multicenter trials and theranostic program development, but divergent reimbursement frameworks necessitate tailored health economic narratives and country-specific access strategies. Meanwhile, emerging centers in the Middle East and Africa are investing in nuclear medicine capacity, presenting opportunities for capacity-building partnerships and phased market development.

Asia-Pacific encompasses a wide spectrum from highly developed healthcare systems with robust regulatory infrastructure to rapidly expanding markets that prioritize capacity expansion. Regional differences in isotope production capabilities, imaging infrastructure, and clinical practice patterns influence site selection for trials and commercial rollouts. Consequently, a segmented regional strategy that aligns clinical evidence generation with local production capabilities and payer expectations is essential for effective deployment across these territories.

Analyzing corporate strategies that combine platform differentiation, manufacturing control, and clinical integration to strengthen competitive advantage in radiopharmaceuticals

Key company-level dynamics in the PSMA radionuclide arena revolve around strategic partnerships, vertical integration of radiochemistry capabilities, and the orchestration of clinical-development ecosystems. Leading developers emphasize platform versatility, enabling candidates to be paired with multiple radionuclides to optimize therapeutic indices and to support theranostic use. Collaborative models that link radiopharmaceutical developers with cyclotron operators, specialty pharmacies, and academic clinical sites are increasingly prevalent because they address both production constraints and site readiness for complex handling and administration.

At the corporate level, differentiation often emerges through intellectual property around targeting moieties, linker chemistry, and radiolabeling processes, as well as through proprietary manufacturing workflows that improve yield and reduce decay losses. Companies that invest in modular manufacturing technologies and in-house radiochemistry expertise tend to achieve greater control over supply continuity and quality assurance. Additionally, firms that proactively engage with regulatory bodies, payer stakeholders, and multidisciplinary clinical consortia are more effective at aligning clinical programs with real-world evidence requirements and access pathways.

Competitive positioning also depends on the ability to demonstrate physician adoption and to embed therapies into established care pathways. Organizations that support site training, offer turnkey logistics solutions, and design pragmatic clinical programs that respect operational constraints gain traction more quickly. In sum, the most resilient companies are those that integrate scientific differentiation with operational execution and stakeholder alignment across the development-to-delivery continuum.

Actionable strategic pillars for senior executives to secure supply resilience, regulatory alignment, and clinical adoption for PSMA radionuclide therapies

Industry leaders must adopt a multipronged strategy to convert scientific promise into durable clinical and commercial outcomes for PSMA-targeted radionuclide conjugates. First, investing in flexible production models that reduce dependence on single-source supply and that can be co-located with key trial sites will mitigate logistical barriers intrinsic to short-lived isotopes. Coupled with this, establishing long-term supplier agreements and redundancy for critical precursors and equipment reduces exposure to trade-related and geopolitical disruptions.

Second, forging early and transparent engagement with regulators and payers helps shape feasible evidence generation plans that balance accelerated access with comprehensive safety and value demonstration. Strategic clinical designs that incorporate robust imaging-based selection criteria, relevant patient-reported outcomes, and pragmatic endpoints can expedite adoption while addressing payer concerns. Third, building integrated commercial models that include specialist training, logistics support, and clear clinical pathways for administration will facilitate uptake among hospitals, clinics, and imaging centers. Finally, partnering with research institutions and specialty pharmacies to create end-to-end service offerings enhances site readiness and ensures that operational workflows align with therapeutic protocols, thereby accelerating real-world implementation.

Methodological transparency describing expert interviews, technical literature synthesis, and operational analysis underpinning the report's findings and recommendations

This research synthesis is informed by a multi-method approach that integrates primary interviews with subject-matter experts, secondary literature review of peer-reviewed clinical studies and regulatory guidance, and operational analysis of radiopharmacy and logistics practices. Expert consultations included clinicians specializing in nuclear medicine and medical oncology, regulatory affairs professionals with radiopharmaceutical experience, manufacturing and supply chain leads from radiochemistry enterprises, and clinical operations specialists involved in complex trial execution. These engagements provided qualitative insights into clinical decision-making, site readiness, and the operational constraints of isotope handling.

Secondary evidence was drawn from recent clinical trial publications, regulatory approvals and guidance documents, and publicly available technical literature on radionuclide production and radiochemistry methodologies. Operational analysis focused on production workflows for Actinium-225, Gallium-68, Lutetium-177, and Technetium-99m, the logistical implications of half-life and decay, and the infrastructure requirements of hospitals, clinics, and specialty pharmacies. Throughout the methodology, triangulation was applied to reconcile divergent perspectives and to ensure the report's findings are grounded in corroborated evidence and practical operational realities.

Synthesis of clinical, operational, and commercial imperatives that define success for PSMA radionuclide therapeutics and the collaborative path to broader clinical integration

The cumulative analysis underscores that PSMA-targeted radionuclide drug conjugates represent a paradigm shift in prostate cancer care that harnesses the complementarity of imaging and therapy to enable precision interventions. Technological advances in radionuclide selection, coupled with improved imaging and clinical pathway integration, are expanding therapeutic possibilities while bringing to the fore manufacturing, regulatory, and reimbursement challenges that must be managed proactively. Success in this space depends not only on clinical efficacy but equally on operational execution, supply chain resilience, and stakeholder alignment across healthcare ecosystems.

Looking forward, organizations that prioritize adaptable production models, design evidence strategies that satisfy both regulators and payers, and invest in comprehensive site support programs will be best positioned to convert clinical promise into routine clinical practice. The intersection of radiochemistry innovation, pragmatic clinical trial design, and purposeful commercial planning creates an opportunity to deliver meaningful patient benefit while establishing sustainable business models for a new generation of theranostic agents. Ultimately, achieving widespread clinical integration will require coordinated efforts across industry, academia, clinical networks, and policy stakeholders to align incentives and to scale responsible access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted PSMA Radionuclide Drug Conjugates Market, by Radionuclide Type

  • 8.1. Actinium-225
  • 8.2. Gallium-68
  • 8.3. Lutetium-177
  • 8.4. Technetium-99m

9. Targeted PSMA Radionuclide Drug Conjugates Market, by Indication

  • 9.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.2. Metastatic Castration-Sensitive Prostate Cancer
  • 9.3. Non-Metastatic Prostate Cancer

10. Targeted PSMA Radionuclide Drug Conjugates Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Targeted PSMA Radionuclide Drug Conjugates Market, by Patient Age Group

  • 11.1. Adult 18-65
  • 11.2. Senior 65+

12. Targeted PSMA Radionuclide Drug Conjugates Market, by End User

  • 12.1. Clinic
  • 12.2. Hospital
  • 12.3. Imaging Center
  • 12.4. Research Institute

13. Targeted PSMA Radionuclide Drug Conjugates Market, by Distribution Channel

  • 13.1. Direct Purchase
  • 13.2. Hospital Pharmacy
  • 13.3. Specialty Pharmacy

14. Targeted PSMA Radionuclide Drug Conjugates Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Targeted PSMA Radionuclide Drug Conjugates Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Targeted PSMA Radionuclide Drug Conjugates Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Targeted PSMA Radionuclide Drug Conjugates Market

18. China Targeted PSMA Radionuclide Drug Conjugates Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Actinium Pharmaceuticals, Inc.
  • 19.6. ACUITY Pharmaceuticals, Inc.
  • 19.7. Advanced Accelerator Applications
  • 19.8. Bayer AG
  • 19.9. Curium Pharma S.A.
  • 19.10. Endocyte Therapeutics GmbH
  • 19.11. GE Healthcare Limited
  • 19.12. Isoray Medical, Inc.
  • 19.13. ITM Isotope Technologies Munich SE
  • 19.14. Jubilant Life Sciences Limited
  • 19.15. Lantheus Holdings, Inc.
  • 19.16. Novartis AG
  • 19.17. Point Biopharma Global Inc.
  • 19.18. Point Biopharma Inc.
  • 19.19. PSMA Therapeutics LLC
  • 19.20. RadioMedix, Inc.
  • 19.21. Sorrento Therapeutics, Inc.
  • 19.22. Telix Pharmaceuticals Limited
  • 19.23. Telix Pharmaceuticals Pty Ltd
  • 19.24. Theragnostics, Inc.
  • 19.25. Viamet Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GALLIUM-68, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY TECHNETIUM-99M, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY NON-METASTATIC PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY ADULT 18-65, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SENIOR 65+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY IMAGING CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DIRECT PURCHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY RADIONUCLIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA TARGETED PSMA RADIONUCLIDE DRUG CONJUGATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)